Clinicopathological data of 88 MM/MGUS patients
| . | CGH/allelotyping/FISH . | Gene expression, MM . | |
|---|---|---|---|
| MGUS . | MM . | ||
| No. patients | 19 | 41 | 28 |
| Disease type and stage, no. patients | |||
| Early, stage 1/smoldering/indolent | — | 14 | 6 |
| Advanced, stage 2/3 | — | 27 | 22 |
| Sex, no. men/no. women (ratio) | 12/7 (1.71:1) | 20/21 (0.95:1) | 17/11 (1.55:1) |
| Isotype | |||
| IgG:IgA:IgM:light chain | 12:5:1:1 | 22:17:0:2 | 13:11:0:3 |
| κ:λ | 10:9 | 17:24 | 16:12 |
| Median follow-up, mo | 23 | 24.5 | NA |
| Impaired renal function, no. patients | 0 | 9 | 9 |
| Immunosuppression, no. patients | 0 | 29 | 23 |
| Bence Jones protein, no. patients | 7 | 26 | 20 |
| Median age, y (range) | 76 (49-88) | 71 (46-87) | 68 (50-86) |
| Median hemoglobin level, g/dL (range) | 10.4 (7.3-13.8) | 9.3 (4-14.5) | 8.5 (5.6-14.5) |
| Median white cell count, × 109/L (range) | 7.4 (2.9-10.7) | 5.3 (0.92-72.1) | 5.95 (2.3-9.9) |
| Median platelet count, × 109/L (range) | 246 (121-547) | 192 (26-509) | 255 (128-561) |
| Median creatinine level, μmol/L (range) | 91 (55-148) | 91 (51-1053) | 102 (57-322) |
| Median calcium level, mmol/L (range) | 2.33 (1.93-2.8) | 2.23 (1.88-2.77) | 2.5 (2.08-3) |
| Median albumin level, g/L (range) | 34 (17-49) | 32.5 (17-45) | 33 (17-42) |
| Median C-reactive protein level, mg/L (range) | 4.45 (3.9-8.8) | 7.7 (3.9-149) | 9 (1-98) |
| Median serum paraprotein level, g/L (range) | 8.2 (2.4-17.5) | 23.6 (0-77.2) | 41.2 (0-78.6) |
| Median % bone marrow plasma cells (range) | 7 (3-10) | 37 (5-100) | 54 (7-95) |
| . | CGH/allelotyping/FISH . | Gene expression, MM . | |
|---|---|---|---|
| MGUS . | MM . | ||
| No. patients | 19 | 41 | 28 |
| Disease type and stage, no. patients | |||
| Early, stage 1/smoldering/indolent | — | 14 | 6 |
| Advanced, stage 2/3 | — | 27 | 22 |
| Sex, no. men/no. women (ratio) | 12/7 (1.71:1) | 20/21 (0.95:1) | 17/11 (1.55:1) |
| Isotype | |||
| IgG:IgA:IgM:light chain | 12:5:1:1 | 22:17:0:2 | 13:11:0:3 |
| κ:λ | 10:9 | 17:24 | 16:12 |
| Median follow-up, mo | 23 | 24.5 | NA |
| Impaired renal function, no. patients | 0 | 9 | 9 |
| Immunosuppression, no. patients | 0 | 29 | 23 |
| Bence Jones protein, no. patients | 7 | 26 | 20 |
| Median age, y (range) | 76 (49-88) | 71 (46-87) | 68 (50-86) |
| Median hemoglobin level, g/dL (range) | 10.4 (7.3-13.8) | 9.3 (4-14.5) | 8.5 (5.6-14.5) |
| Median white cell count, × 109/L (range) | 7.4 (2.9-10.7) | 5.3 (0.92-72.1) | 5.95 (2.3-9.9) |
| Median platelet count, × 109/L (range) | 246 (121-547) | 192 (26-509) | 255 (128-561) |
| Median creatinine level, μmol/L (range) | 91 (55-148) | 91 (51-1053) | 102 (57-322) |
| Median calcium level, mmol/L (range) | 2.33 (1.93-2.8) | 2.23 (1.88-2.77) | 2.5 (2.08-3) |
| Median albumin level, g/L (range) | 34 (17-49) | 32.5 (17-45) | 33 (17-42) |
| Median C-reactive protein level, mg/L (range) | 4.45 (3.9-8.8) | 7.7 (3.9-149) | 9 (1-98) |
| Median serum paraprotein level, g/L (range) | 8.2 (2.4-17.5) | 23.6 (0-77.2) | 41.2 (0-78.6) |
| Median % bone marrow plasma cells (range) | 7 (3-10) | 37 (5-100) | 54 (7-95) |